Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 2/20 | 0.39 |
| ▸ | MGMT | P16455 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791733 | 0.80 | ADORA2B (0.46) | CTSBADORA2AADORA2BKDM4EMAPT | |
| SCHEMBL4052641 | 0.80 | ADORA2A (0.48) | DPP4ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3791610 | 0.79 | CTSB (0.41) | CTSBADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL995894 | 0.78 | CTSB (0.44) | CTSBDPP4ADORA2AMGMTMEN1 | |
| SCHEMBL3791734 | 0.78 | DHFR (0.40) | CTSBMEN1KMT2AMAPTMAP4K4 | |
| SCHEMBL4052643 | 0.77 | DYRK1A (0.49) | DPP4ADORA2AADORA1ADORA2BMGMT | |
| SCHEMBL3791614 | 0.77 | DYRK1A (0.45) | CTSBADORA2AADORA2BMEN1KMT2A | |
| SCHEMBL24549836 | 0.75 | ALDH1A1 (0.44) | CTSBMEN1KMT2AMAPTATM | |
| SCHEMBL4054189 | 0.73 | PIK3R1 (0.47) | CTSBADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL4052650 | 0.73 | CTSB (0.41) | CTSBADORA2AADORA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1942469-B | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB | 2010-07-07 | — | — | CN | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| CN-1942469-A | Condensed pyridine derivatives useful as A28 adenosine receptor antagonists | ALMIRALL LAB (ES) | 2007-04-04 | — | — | CN | disclosed |
| EP-1735310-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005100353-A1 | CONDENSED PYRIDINE DERIVATIVES USEFUL AS A28 ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA, SA (ES) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | CTSB 1190/4885DPP4 3181/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.